X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (71) 71
humans (60) 60
oncology (58) 58
hematology (48) 48
apoptosis (32) 32
animals (31) 31
signal transduction (27) 27
acute myeloid-leukemia (26) 26
research (26) 26
apoptosis - drug effects (21) 21
mice (20) 20
health aspects (19) 19
genetic aspects (17) 17
physiological aspects (16) 16
akt (15) 15
colony-stimulating factor (15) 15
signal transduction - drug effects (15) 15
targeted therapy (15) 15
acute lymphoblastic-leukemia (14) 14
leukemia (14) 14
phosphatidylinositol 3-kinases - metabolism (14) 14
signal-transduction (14) 14
raf (13) 13
cancer (12) 12
chemotherapy (11) 11
cytokines (11) 11
drug therapy (11) 11
nf-kappa-b (11) 11
phosphatidylinositol 3-kinases - antagonists & inhibitors (11) 11
phosphorylation (11) 11
acute myelogenous leukemia (10) 10
antineoplastic agents - pharmacology (10) 10
blotting, western (10) 10
cellular signal transduction (10) 10
drug resistance (10) 10
interleukin-3 - pharmacology (10) 10
oncogenes (10) 10
pi3k (10) 10
apoptosis - physiology (9) 9
autocrine transformation (9) 9
mtor (9) 9
proto-oncogene proteins c-akt - metabolism (9) 9
rna, messenger - genetics (9) 9
activated protein-kinase (8) 8
acute lymphocytic leukemia (8) 8
biochemistry & molecular biology (8) 8
care and treatment (8) 8
cell line (8) 8
cell line, tumor (8) 8
flow cytometry (8) 8
gene expression (8) 8
hematopoietic cells (8) 8
hematopoietic-cells (8) 8
leukemia - drug therapy (8) 8
protein kinases (8) 8
protein kinases - metabolism (8) 8
proto-oncogene proteins c-akt - antagonists & inhibitors (8) 8
tor serine-threonine kinases (8) 8
abrogate cytokine dependency (7) 7
antineoplastic agents - therapeutic use (7) 7
cell division - drug effects (7) 7
cell proliferation - drug effects (7) 7
chronic lymphocytic-leukemia (7) 7
enzyme inhibitors - pharmacology (7) 7
gm-csf (7) 7
male (7) 7
risk factors (7) 7
tumor cells, cultured (7) 7
akt inhibitor (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
article (6) 6
base sequence (6) 6
cell cycle (6) 6
cell cycle - drug effects (6) 6
drug synergism (6) 6
estradiol - pharmacology (6) 6
female (6) 6
gene-expression (6) 6
growth (6) 6
hematopoietic stem cells - physiology (6) 6
il-3 (6) 6
kinases (6) 6
mammalian target (6) 6
mitogen-activated protein kinase 1 - metabolism (6) 6
mitogen-activated protein kinases - metabolism (6) 6
phosphatidylinositol 3-kinases - physiology (6) 6
proteins (6) 6
resistance (6) 6
reverse transcriptase polymerase chain reaction (6) 6
rna, messenger - metabolism (6) 6
signal transduction - physiology (6) 6
cell division (5) 5
cell survival - drug effects (5) 5
chemotherapeutic drugs (5) 5
combination therapy (5) 5
drug design (5) 5
drug resistance, neoplasm (5) 5
enzyme activation (5) 5
enzyme inhibitors (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 2002, Volume 16, Issue 4, pp. 486 - 507
Journal Article
Leukemia, ISSN 0887-6924, 06/2008, Volume 22, Issue 6, pp. 1106 - 1116
A significant impediment to the success of cancer chemotherapy is the occurrence of multidrug resistance, which, in many cases, is attributable to... 
CANCER-CELLS | MULTIPLE-MYELOMA | targeted therapy | ACTIVATION | KINASE | apoptosis | DEATH | ACUTE MYELOID-LEUKEMIA | PI3K/Akt | ONCOLOGY | PATHWAY | perifosine | ACUTE LYMPHOBLASTIC-LEUKEMIA | LIPID RAFTS | drug resistance | HEMATOLOGY | PHASE-I | Apoptosis - drug effects | Drug Resistance, Multiple | Membrane Microdomains - metabolism | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Drug Resistance, Neoplasm | JNK Mitogen-Activated Protein Kinases - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Phosphorylcholine - analogs & derivatives | RNA, Messenger - metabolism | Immunoenzyme Techniques | Caspases - metabolism | Flow Cytometry | Phosphorylcholine - pharmacology | Electrophoretic Mobility Shift Assay | JNK Mitogen-Activated Protein Kinases - genetics | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | BH3 Interacting Domain Death Agonist Protein - metabolism | Cell Survival - drug effects | JNK Mitogen-Activated Protein Kinases - antagonists & inhibitors | Signal Transduction | Cytochromes c - metabolism | Down-Regulation | RNA, Messenger - genetics | RNA, Small Interfering - pharmacology | Mitochondria - metabolism | Leukemia-Lymphoma, Adult T-Cell - pathology | Mitochondria - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Leukemia-Lymphoma, Adult T-Cell - metabolism | Vinblastine - pharmacology | Enzyme Activation | Antineoplastic Agents, Phytogenic - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Care and treatment | Enzyme inhibitors | Genetic aspects | Dosage and administration | Glycoproteins | Acute lymphocytic leukemia | Health aspects | Protein kinases | Index Medicus
Journal Article
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 01/2013, Volume 20, Issue 1, pp. 144 - 157
Journal Article
Leukemia, ISSN 0887-6924, 05/2011, Volume 25, Issue 5, pp. 781 - 791
Journal Article
Leukemia, ISSN 0887-6924, 03/2007, Volume 21, Issue 3, pp. 427 - 438
A high incidence of relapses following induction chemotherapy is a major hindrance to patient survival in acute myelogenous leukemia (AML). There is strong... 
AML | PERIPHERAL-BLOOD | ACUTE MYELOID-LEUKEMIA | DRUG-RESISTANCE | PI3K/Akt | p53 | P-GLYCOPROTEIN | HEMATOPOIETIC-CELLS | PI3K/AKT PATHWAY | SOUTHWEST-ONCOLOGY-GROUP | ONCOLOGY | PROSTATE-CANCER CELLS | MDM2 | GENE-EXPRESSION | drug resistance | CYCLE PROGRESSION | HEMATOLOGY | Leukocytes, Mononuclear - metabolism | Phosphorylation | Proto-Oncogene Proteins c-mdm2 - genetics | Leukemia, Promyelocytic, Acute - pathology | Tumor Suppressor Protein p53 - biosynthesis | Jurkat Cells - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myeloid - genetics | Middle Aged | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Fluorescent Dyes - metabolism | Male | Cell Line, Tumor - drug effects | Multidrug Resistance-Associated Proteins - biosynthesis | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Bone Neoplasms - pathology | Gene Expression Regulation, Leukemic - genetics | Leukemia, Myeloid - pathology | Genes, p53 | Neoplastic Stem Cells - metabolism | Aged, 80 and over | Adult | Female | Multidrug Resistance-Associated Proteins - genetics | Neoplasm Proteins - genetics | Cell Line, Tumor - metabolism | Proto-Oncogene Proteins c-mdm2 - biosynthesis | Acute Disease | Leukocytes, Mononuclear - drug effects | Neoplasm Proteins - biosynthesis | Gene Expression Regulation, Leukemic - drug effects | Proto-Oncogene Proteins c-akt - physiology | Leukemia-Lymphoma, Adult T-Cell - pathology | Gene Expression Regulation, Leukemic - physiology | Rhodamine 123 - metabolism | Drug Resistance, Neoplasm - genetics | Androstadienes - pharmacology | Leukemia, Myeloid - metabolism | Phosphatidylinositol 3-Kinases - physiology | Aged | Protein Processing, Post-Translational | Osteosarcoma - pathology | Jurkat Cells - drug effects | Complications and side effects | Chemotherapy | Research | Drug resistance | Health aspects | Risk factors | Cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Cell death & disease, ISSN 2041-4889, 06/2016, Volume 7, Issue 6, pp. e2269 - e2269
Sorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are... 
BREAST-CANCER | APOPTOSIS | HEPATOCELLULAR-CARCINOMA | TUMOR PROGRESSION | ER STRESS | BONE MORPHOGENETIC PROTEIN-7 | ENDOPLASMIC-RETICULUM STRESS | IDENTIFICATION | EXPRESSION | RAF/MEK/ERK PATHWAY | CELL BIOLOGY | Niacinamide - analogs & derivatives | Gene Silencing - drug effects | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Cell Survival - genetics | Male | Gene Expression Profiling | Molecular Targeted Therapy | Neoplasm Proteins - metabolism | Core Binding Factor Alpha 1 Subunit - metabolism | Cell Movement - genetics | Gene Knockdown Techniques | Young Adult | Basic Helix-Loop-Helix Transcription Factors - metabolism | Carcinoma, Hepatocellular - genetics | Aged, 80 and over | Apoptosis Regulatory Proteins - genetics | Female | Liver Neoplasms - pathology | Membrane Proteins - metabolism | Neoplasm Proteins - genetics | Transcription Factor RelB - genetics | Cell Survival - drug effects | Cell Proliferation - genetics | Basic Helix-Loop-Helix Transcription Factors - genetics | Liver Neoplasms - genetics | Membrane Proteins - genetics | Neoplasm Invasiveness | Computational Biology | Transcriptome - genetics | Down-Regulation - drug effects | Apoptosis Regulatory Proteins - metabolism | Cell Movement - drug effects | Transcription Factor RelB - metabolism | Carcinoma, Hepatocellular - pathology | Aged | Cell Proliferation - drug effects | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Drug Resistance, Neoplasm - drug effects | RNA, Small Interfering - metabolism | Proteins | Liver cancer | Cell growth | Cell adhesion & migration | Index Medicus | Original
Journal Article
Oncogene, ISSN 0950-9232, 07/2008, Volume 27, Issue 29, pp. 4086 - 4095
Ectopic expression of mutant forms of phosphatase and tensin homologue deleted on chromosome 10 ( PTEN) lacking lipid ( G129E) or lipid and protein ( C124S)... 
mTOR | PTEN | Akt | Chemotherapeutic drugs | Rap amycin | MAMMALIAN TARGET | CELLS | ACTIVATION | PROTEIN-KINASE-B | BIOCHEMISTRY & MOLECULAR BIOLOGY | chemotherapeutic drugs | PHOSPHOINOSITIDE 3-KINASE | INVASIVE DUCTAL CARCINOMA | COWDEN-DISEASE | CELL BIOLOGY | AKT ACTIVITY | ONCOLOGY | GENETICS & HEREDITY | THERAPEUTIC INTERVENTION | REDUCED EXPRESSION | rapamycin | Doxorubicin - agonists | Protein Kinases - metabolism | Doxorubicin - therapeutic use | Protein Kinases - genetics | Antibiotics, Antineoplastic - pharmacology | Humans | Mutation, Missense | Proto-Oncogene Proteins c-akt - genetics | PTEN Phosphohydrolase - antagonists & inhibitors | Breast Neoplasms - enzymology | Transfection | Female | Proto-Oncogene Proteins c-akt - metabolism | Antibiotics, Antineoplastic - agonists | PTEN Phosphohydrolase - genetics | Gene Expression | Sirolimus - therapeutic use | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | PTEN Phosphohydrolase - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - genetics | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Sirolimus - agonists | Drug Synergism | Drug Resistance, Neoplasm - genetics | Breast Neoplasms - genetics | Antibiotics, Antineoplastic - therapeutic use | Signal Transduction - drug effects | Cell Line, Tumor | TOR Serine-Threonine Kinases | Doxorubicin - pharmacology | Amino Acid Substitution | Drug Resistance, Neoplasm - drug effects | Enzyme inhibitors | Causes of | Physiological aspects | Tumor suppressor genes | Breast cancer | Genetic aspects | Dosage and administration | Research | Drug therapy | Drug resistance | Health aspects | Risk factors | Genetics | Chemotherapy | Inhibitor drugs | Mutation | Index Medicus | Chemotherapeutic Drugs | Rapamycin
Journal Article